Helix Biopharma (HBPCF) to Release Quarterly Earnings on Monday

Helix Biopharma (OTCMKTS:HBPCF) is anticipated to announce its resultson Monday, June 15th. Analysts expect the company to announce earnings of ($0.0783) per share for the quarter.

Helix Biopharma (OTCMKTS:HBPCF) last issued its quarterly earnings data on Monday, March 16th. The company reported ($0.01) earnings per share for the quarter.

Helix Biopharma Stock Performance

Shares of OTCMKTS:HBPCF opened at $1.71 on Monday. The company has a market capitalization of $130.61 million, a PE ratio of -34.20 and a beta of 0.17. Helix Biopharma has a twelve month low of $1.71 and a twelve month high of $1.73. The firm has a 50 day simple moving average of $1.72 and a 200-day simple moving average of $1.73.

About Helix Biopharma

Helix BioPharma Corp is a clinical‐stage biotechnology company focused on the research, development and commercialization of immunotherapeutic drug candidates for oncology and rare disease indications. Headquartered in Laval, Quebec, the company leverages proprietary platforms designed to activate or modulate the immune system, with programs spanning small‐molecule immunoconjugates and biologic modalities. Its lead candidate, L-DOS47, is an antibody‐based immunoconjugate in clinical evaluation for non–small cell lung cancer, and Helix maintains additional discovery‐stage assets targeting solid tumors and hematological malignancies.

Founded in 1983, Helix BioPharma has built a global network of collaborations with academic research centers and contract research organizations across North America and Europe.